ADCT ADC Pharma: ערך חשבונאי למניה

Biotechnology startup ADC Therapeutics (ADCT) relies on the work of research laboratories, strictly adhering to hazardous waste disposal standards and energy efficiency. ADC Therapeutics (ADCT) is developing a targeted tumor destruction system through innovative antibody-drug conjugates, establishing itself as a leader in therapy. The -1.77 metric complements data on social responsibility and testing ethics. This price chart clearly illustrates the market dynamics of this developer of blood cancer drugs.

Book value per share reflects the issuer's net assets minus liabilities, representing a fundamental "floor" for the business valuation. By analyzing the book value per share, an investor can assess the actual resource backing of ADC Therapeutics (ADCT), which is critically important given the company's high cash burn and its struggle for market share in the oncology drug segment.